SAN FRANCISCO--(BUSINESS WIRE)--Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the results of recent testing of the unique PVA film formulation produced by Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. Earlier this week, Biomagnetics announced its intent to acquire Lanzhou as the first of several planned acquisitions to be done at a $1.00 share price valuation for Biomagnetics Diagnostics’ common shares.
